These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 29735368)

  • 1. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
    Dall'Era MA; deVere-White R; Rodriguez D; Cress R
    Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.
    Suresh T; Sharma J; Goel S; Kovac E; Gao Q; Gartrell B
    Clin Genitourin Cancer; 2019 Apr; 17(2):139-144. PubMed ID: 30655076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
    Kelly SP; Anderson WF; Rosenberg PS; Cook MB
    Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation.
    Kensler KH; Pernar CH; Mahal BA; Nguyen PL; Trinh QD; Kibel AS; Rebbeck TR
    J Natl Cancer Inst; 2021 Jun; 113(6):719-726. PubMed ID: 33146392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
    Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
    JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race.
    Kelly SP; Rosenberg PS; Anderson WF; Andreotti G; Younes N; Cleary SD; Cook MB
    Eur Urol; 2017 Feb; 71(2):195-201. PubMed ID: 27476048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial and ethnic disparities in gallbladder cancer: A two-decade analysis of incidence and mortality rates in the US.
    Abboud Y; Singh L; Fraser M; Pan CW; Abboud I; Mohamed IH; Kim D; Alsakarneh S; Jaber F; Richter B; Al-Khazraji A; Hajifathalian K; Vossough-Teehan S
    Cancer Med; 2024 Jul; 13(13):e7457. PubMed ID: 38963040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
    JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses.
    Dalela D; Sun M; Diaz M; Karabon P; Seisen T; Trinh QD; Menon M; Abdollah F
    Eur Urol Focus; 2019 Jan; 5(1):77-80. PubMed ID: 28753893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
    Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S
    Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation.
    Lai SM; Keighley J; Garimella S; Enko M; Parker WP
    JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Incidence of Metastatic Prostate Cancer in the US.
    Desai MM; Cacciamani GE; Gill K; Zhang J; Liu L; Abreu A; Gill IS
    JAMA Netw Open; 2022 Mar; 5(3):e222246. PubMed ID: 35285916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
    Bernard B; Muralidhar V; Chen YH; Sridhar SS; Mitchell EP; Pettaway CA; Carducci MA; Nguyen PL; Sweeney CJ
    Cancer; 2017 May; 123(9):1536-1544. PubMed ID: 28055108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
    Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
    Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
    Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment.
    Cook MB; Hurwitz LM; Geczik AM; Butler EN
    Eur Urol; 2021 Jan; 79(1):33-41. PubMed ID: 33092896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial and Ethnic Trends in Prostate Cancer Incidence and Mortality in Philadelphia, PA: an Observational Study.
    Zeigler-Johnson C; Keith S; McIntire R; Robinson T; Leader A; Glanz K
    J Racial Ethn Health Disparities; 2019 Apr; 6(2):371-379. PubMed ID: 30520002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer.
    Iyer HS; Stone BV; Roscoe C; Hsieh MC; Stroup AM; Wiggins CL; Schumacher FR; Gomez SL; Rebbeck TR; Trinh QD
    JAMA Netw Open; 2024 Jun; 7(6):e2414582. PubMed ID: 38833252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study.
    Katz JE; Chinea FM; Patel VN; Balise RR; Venkatramani V; Gonzalgo ML; Ritch C; Pollack A; Parekh DJ; Punnen S
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):533-538. PubMed ID: 29988097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
    Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
    Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.